The Peritoneal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Peritoneal Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peritoneal Cancer Market.

Some of the key takeaways from the Peritoneal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Peritoneal Cancer treatment therapies with a considerable amount of success over the years. 

• Peritoneal Cancer companies working in the treatment market are AB Science, Zentalis Pharmaceuticals, ImmunoGen, Hoffmann-La Roche, Corcept Therapeutics, Memorial Sloan Kettering Cancer Center, LintonPharm Co.,Ltd., M.D. Anderson Cancer Center, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Kancera AB, Haider Mahdi, RemeGen Co., Ltd., Hansoh BioMedical, OncXerna Theraputics, Inc, and others, are developing therapies for the Peritoneal Cancer treatment 

• Emerging Peritoneal Cancer therapies in the different phases of clinical trials are- Masitinib, Azenosertib, IMGN151, Bevacizumab, Nab-paclitaxel, 131 I-omburtamab, Catumaxomab, Fulvestrant, Bevacizumab, Carboplatin, MORAb-202, KAND567, ZEN003694, RC88, HS-20089, navicixizumab, and others are expected to have a significant impact on the Peritoneal Cancer market in the coming years.   

• In January 2024, The FDA has awarded fast track designation (FTD) to RC88 for treating platinum-resistant ovarian, fallopian tube, and peritoneal cancers. RC88 is an innovative antibody-drug conjugate (ADC) that targets mesothelin (MSLN).

• In November 2023, The US Food and Drug Administration (FDA) has approved Oncoinvent’s investigational new drug (IND) application, allowing the initiation of a Phase II clinical trial for Radspherin in treating ovarian cancer-related peritoneal carcinomatosis. Oncoinvent intends to start the trial in the second quarter of the following year. This controlled, randomized trial will assess the safety and effectiveness of Radspherin.

• In January 2022, Avenge Bio announced the completion of its Series A financing, raising $45 million. This financing round was co-led by Perceptive Xontogeny Venture Fund and CAM Capital, with participation from seed investor Longitude Capital and new investors Rock Springs Capital and Pappas Capital. The proceeds will be used to advance Avenge Bio’s lead program, AVB-001, through the filing of an Investigational New Drug (IND) application and into clinical trials for treating metastatic peritoneal cancers, focusing primarily on recurrent and refractory ovarian cancer.

Peritoneal Cancer Overview

Peritoneal cancer is a rare type of cancer that occurs in the peritoneum, a thin layer of tissue that lines the abdomen and covers most of its organs. It is closely related to ovarian cancer and can cause similar symptoms. Peritoneal cancer can be primary, originating in the peritoneum itself, or secondary, spreading from other organs such as the ovaries, stomach, or colon. Symptoms may include abdominal pain or swelling, digestive issues, and unexplained weight loss. Treatment typically involves surgery, chemotherapy, and targeted therapies, depending on the cancer’s origin and stage.

Get a Free Sample PDF Report to know more about Peritoneal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight

Emerging Peritoneal Cancer Drugs Under Different Phases of Clinical Development Include:

• Masitinib: AB Science

• Azenosertib: Zentalis Pharmaceuticals

• IMGN151: ImmunoGen

• Bevacizumab: Hoffmann-La Roche

• Nab-paclitaxel: Corcept Therapeutics

• 131 I-omburtamab: Memorial Sloan Kettering Cancer Center

• Catumaxomab: LintonPharm Co.,Ltd.

• Fulvestrant: M.D. Anderson Cancer Center

• Bevacizumab: ImmunoGen, Inc.

• Carboplatin: Merck Sharp & Dohme LLC

• MORAb-202: Bristol-Myers Squibb

• KAND567: Kancera AB

• ZEN003694: Haider Mahdi

• RC88: RemeGen Co., Ltd.

• HS-20089: Hansoh BioMedical

• navicixizumab: OncXerna Theraputics, Inc

Peritoneal Cancer Route of Administration

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Peritoneal Cancer Molecule Type

Peritoneal Cancer Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Peritoneal Cancer Pipeline Therapeutics Assessment

• Peritoneal Cancer Assessment by Product Type

• Peritoneal Cancer By Stage and Product Type

• Peritoneal Cancer Assessment by Route of Administration

• Peritoneal Cancer By Stage and Route of Administration

• Peritoneal Cancer Assessment by Molecule Type

• Peritoneal Cancer by Stage and Molecule Type

DelveInsight’s Peritoneal Cancer Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Peritoneal Cancer product details are provided in the report. Download the Peritoneal Cancer pipeline report to learn more about the emerging Peritoneal Cancer therapies

Some of the key companies in the Peritoneal Cancer Therapeutics Market include:

Key companies developing therapies for Peritoneal Cancer are – Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck & Co, AstraZeneca, Lee’s Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Astex Pharmaceuticals, APIM Therapeutics, Celsion, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, Alkermes, Zenith Epigenetics, Sutro Biopharma, K-Group Beta, Bio-Path Holdings, Celldex Therapeutics, Rhizen Pharmaceuticals, Shattuck Labs, Inc., SELLAS Life Sciences Group, LIPAC oncology, Oncoinvent AS, Mereo Biopharma, Solasia Pharma, Mersana Therapeutics,  Zentalis Pharmaceuticals, Lumicell Inc., Avenge Bio, and others.

Peritoneal Cancer Pipeline Analysis:

The Peritoneal Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Peritoneal Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.

• Peritoneal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Peritoneal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peritoneal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peritoneal Cancer drugs and therapies

Peritoneal Cancer Pipeline Market Drivers

• Advancements in treatment, increasing Incidence, government Initiatives, collaborative Efforts, patient Advocacy Groups, are some of the important factors that are fueling the Peritoneal Cancer Market.

Peritoneal Cancer Pipeline Market Barriers

• However, clinical Trial Challenges, high Development Costs, regulatory Hurdles, limited treatment Options and other factors are creating obstacles in the Peritoneal Cancer Market growth.

Scope of Peritoneal Cancer Pipeline Drug Insight    

• Coverage: Global

• Key Peritoneal Cancer Companies: AB Science, Zentalis Pharmaceuticals, ImmunoGen, Hoffmann-La Roche, Corcept Therapeutics, Memorial Sloan Kettering Cancer Center, LintonPharm Co.,Ltd., M.D. Anderson Cancer Center, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Kancera AB, Haider Mahdi, RemeGen Co., Ltd., Hansoh BioMedical, OncXerna Theraputics, Inc, and others

• Key Peritoneal Cancer Therapies: Masitinib, Azenosertib, IMGN151, Bevacizumab, Nab-paclitaxel, 131 I-omburtamab, Catumaxomab, Fulvestrant, Bevacizumab, Carboplatin, MORAb-202, KAND567, ZEN003694, RC88, HS-20089, navicixizumab, and others

• Peritoneal Cancer Therapeutic Assessment: Peritoneal Cancer current marketed and Peritoneal Cancer emerging therapies

• Peritoneal Cancer Market Dynamics: Peritoneal Cancer market drivers and Peritoneal Cancer market barriers 

Request for Sample PDF Report for Peritoneal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Peritoneal Cancer Report Introduction

2. Peritoneal Cancer Executive Summary

3. Peritoneal Cancer Overview

4. Peritoneal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Peritoneal Cancer Pipeline Therapeutics

6. Peritoneal Cancer Late Stage Products (Phase II/III)

7. Peritoneal Cancer Mid Stage Products (Phase II)

8. Peritoneal Cancer Early Stage Products (Phase I)

9. Peritoneal Cancer Preclinical Stage Products

10. Peritoneal Cancer Therapeutics Assessment

11. Peritoneal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peritoneal Cancer Key Companies

14. Peritoneal Cancer Key Products

15. Peritoneal Cancer Unmet Needs

16 . Peritoneal Cancer Market Drivers and Barriers

17. Peritoneal Cancer Future Perspectives and Conclusion

18. Peritoneal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/